ImprimisRx NJ: Drug Recall

Recall #D-0060-2023 · 11/09/2022

Class II: Risk

Recall Details

Recall Number
D-0060-2023
Classification
Class II
Product Type
Drug
Recalling Firm
ImprimisRx NJ
Status
Terminated
Date Initiated
11/09/2022
Location
Ledgewood, NJ, United States
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
960 bottles

Reason for Recall

Subpotent Drug: The batches contain less than 90% of the labeled amount of latanoprost.

Product Description

Timolol-Latanoprost (0.5/0.005%) ophthalmic drops, Compounded, 5 mL bottle, Imprimis Rx, Ledgewood, NJ.

Distribution Pattern

Nationwide in the USA

Data from FDA openFDA enforcement reports. This site is not affiliated with or endorsed by the FDA. Recall information may be updated by the FDA at any time.